- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.06. | Genentech's Bittenbender named board chair at BIO | ||
| 16.06. | After rebuffing Biogen, Sage pairs off with Supernus | ||
| 16.06. | J&J says two drugs are better than one in pretreated myeloma | ||
| 16.06. | Former CEO wins bidding war for 23andMe, beating Regeneron | ||
| 16.06. | DMD gene therapy Elevidys linked to new liver failure case | ||
| 16.06. | Streeting pledges clinical trial signups in the NHS App | ||
| 13.06. | US lawmakers seek ban on DTC advertising | ||
| 13.06. | AZ taps Chinese firm CSPC's AI acumen in $5.2bn+ alliance | ||
| 13.06. | Moderna's RSV shot gets US nod for use in younger adults | ||
| 13.06. | Pushback rises against RFK Jr's new ACIP membership | ||
| 13.06. | NHS starts first national rollout of Blenrep for myeloma | ||
| 13.06. | Data at EULAR back Biogen, UCB's first-in-class lupus drug | ||
| 12.06. | BioNTech to buy rival mRNA firm CureVac for $1.25bn | ||
| 12.06. | MSD aims to plug dengue fever vaccine gap in US | ||
| 12.06. | FDA clears Nuvation's first product Ibtrozi, for lung cancer | ||
| 12.06. | Novo Nordisk teams up with NVIDIA on AI models | ||
| 12.06. | Concerns rise over ACIP's new membership | ||
| 11.06. | Marvel's latest superhero aims to smash diabetes stigma | ||
| 11.06. | UK follows through on doubling of statutory scheme rate | ||
| 11.06. | BMS' radiopharma unit builds with $1.35bn Philochem deal | ||
| 11.06. | SpliceBio gathers $135m for eye disease gene therapies | ||
| 11.06. | Makary, Prasad set out their vision for the FDA | ||
| 10.06. | Most pharmas not ready for AI in customer engagement | ||
| 10.06. | Beyfortus now has a direct rival after FDA OK for Enflonsia | ||
| 10.06. | NewAmsterdam says lead drug may have Alzheimer's role |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .